ABSTRACT
One of the neuropathological hallmarks of the tauopathies is the formation of neuronal cytoplasmic inclusions and fibrils of microtubule-associated tau protein (tau). The phosphorylation of Thr175 of tau (pThr175 tau) appears to be sufficient for fibril formation in vitro and in vivo, but the mechanism by which this initiates fibril formation is unknown. Using transient transfections of tau mutants into HEK293T cells, we determined that the phosphorylation of Thr175 leads to exposure of the tau N-terminal phosphatase-activating domain (PAD). The exposed PAD is known to interact with protein phosphatase-1 (PP1) resulting in glycogen synthase kinase 3ß (GSK3ß) activation. In vivo, a single traumatic controlled cortical injury in rats also resulted in the phosphorylation of Thr175 and increased exposure of tau PAD followed by pathological tau fibril formation. Taken together, these data suggest that neurotoxicity may be precipitated by phosphorylation at Thr175 and subsequent tau PAD exposure, GSK3ß activation and tau fibril formation. Cover Image for this issue: doi: 10.1111/jnc.14767.
Subject(s)
Amyloid/metabolism , Phosphoric Monoester Hydrolases/metabolism , Threonine/metabolism , tau Proteins/metabolism , Animals , Female , Glycogen Synthase Kinase 3 beta/metabolism , HEK293 Cells , Humans , Phosphorylation/physiology , Rats , Rats, Sprague-DawleyABSTRACT
Many disorders of the central nervous system are characterized by both axonal pathology and demyelination. In assessing this concurrent pathology, techniques for staining axons or myelin are frequently used separately. Here we report the development of a combined immunohistochemical and tinctorial staining technique in which we have modified the Luxol fast blue myelin stain to be used in conjunction with a diaminobenzidine-based immunohistochemical stain for high molecular weight neurofilament (SMI-31). This modification of staining will have utility in experimental neuropathology laboratories investigating demyelination and axonal damage in human tissue and animal models.
Subject(s)
Axons/metabolism , Immunohistochemistry/methods , Intermediate Filaments/metabolism , Myelin Sheath/metabolism , Spinal Cord/metabolism , Staining and Labeling/methods , Amyotrophic Lateral Sclerosis , Animals , Axons/pathology , Humans , Indoles , Intermediate Filaments/pathology , Myelin Sheath/pathology , Rats , Rats, Sprague-Dawley , Spinal Cord/pathologyABSTRACT
Amyotrophic lateral sclerosis (ALS) is a devastating progressive neurodegenerative disease with no known etiology. The formation of pathological protein inclusions, including RNA-binding proteins such as TDP-43 and rho guanine nucleotide exchange factor (RGNEF) are a hallmark of ALS. Despite intensive research, the mechanisms behind protein aggregate formation in ALS remains unclear. We have investigated the role of metabolic stress in protein aggregate formation analyzing how it is relevant to the co-aggregation observed between RGNEF and TDP-43 in motor neurons of ALS patients. Metabolic stress was able to induce formation of micronuclei, small nuclear fragments, in cultured cells. Notably, we observed the formation TDP-43 protein inclusions within micronuclei that co-aggregate with RGNEF and can be released to the cytoplasm. We observed that the leucine-rich domain of RGNEF is critical for its interaction with TDP-43 and localization in micronuclei. Finally, we described that micronuclei-like structures can be found in brain and spinal cord of ALS patients. This work is the first description of protein inclusion formation within micronuclei which also is linked with a neurodegenerative disease. The formation of TDP-43 inclusions within micronuclei induced by metabolic stress is a novel mechanism of protein aggregate formation which may have broad relevance for ALS and other neurodegenerative diseases.
Subject(s)
Amyotrophic Lateral Sclerosis/metabolism , DNA-Binding Proteins/metabolism , Amyotrophic Lateral Sclerosis/genetics , Animals , Blotting, Western , DNA-Binding Proteins/genetics , Female , Fluorescent Antibody Technique , HEK293 Cells , Humans , Immunoprecipitation , Inclusion Bodies/metabolism , Motor Neurons/metabolism , Neurodegenerative Diseases/metabolism , Rats , Reactive Oxygen Species/metabolism , Spinal Cord/metabolismABSTRACT
Although it has been suggested that the co-expression of multiple pathological proteins associated with neurodegeneration may act synergistically to induce more widespread neuropathology, experimental evidence of this is sparse. We have previously shown that the expression of Thr175Asp-tau (tauT175D) using somatic gene transfer with a stereotaxically-injected recombinant adeno-associated virus (rAAV9) vector induces tau pathology in rat hippocampus. In this study, we have examined whether the co-expression of human tauT175D with mutant human TDP-43 (TDP-43M337V) will act synergistically. Transgenic female Sprague-Dawley rats that inducibly express mutant human TDP-43M337V using the choline acetyltransferase (ChAT) tetracycline response element (TRE) driver with activity modulating tetracycline-controlled transactivator (tTA) were utilized in these studies. Adult rats were injected with GFP-tagged tau protein constructs in a rAAV9 vector through bilateral stereotaxic injection into the hippocampus. Injected tau constructs were: wild-type GFP-tagged 2N4R human tau (tauWT; n = 8), GFP-tagged tauT175D 2N4R human tau (tauT175D, pseudophosphorylated, toxic variant, n = 8), and GFP (control, n = 8). Six months post-injection, mutant TDP-43M337V expression was induced for 30 days. Behaviour testing identified motor deficits within 3 weeks after TDP-43 expression irrespective of tau expression, though social behaviour and sensorimotor gating remained unchanged. Increased tau pathology was observed in the hippocampus of both tauWT and tauT175D expressing rats and tauT175D pathology was increased in the presence of cholinergic neuronal expression of human TDP-43M337V. These data indicate that co-expression of pathological TDP-43 and tau protein exacerbate the pathology associated with either individual protein.
Subject(s)
DNA-Binding Proteins/metabolism , Hippocampus/metabolism , Hippocampus/physiology , Neurodegenerative Diseases/metabolism , Neurodegenerative Diseases/pathology , tau Proteins/metabolism , Animals , Behavior, Animal , DNA-Binding Proteins/toxicity , Disease Models, Animal , Female , Gene Transfer Techniques , Humans , Motor Activity , Rats, Sprague-Dawley , Rats, Transgenic , Spinal Cord/metabolism , Spinal Cord/pathology , tau Proteins/toxicityABSTRACT
Aberrant phosphorylation of the microtubule associated protein tau (tau) is associated with multiple neurodegenerative diseases where it is a contributes to neurotoxicity. We have observed that phosphorylation at Thr175 tau (pThr175 tau) exerts toxicity when expressed as a pseudophosphorylated tau construct (Thr175Asp) in vitro. To determine whether pThr175 tau can induce tau pathology in vivo with an accompanying clinical phenotype, we used a recombinant adenoviral expression vector (rAAV9) to express a GFP-tagged Thr175Asp tau protein construct in adult female Sprague-Dawley rat hippocampus. Ten rats per group were injected with rAAV9 vectors encoding either GFP, wild type GFP-tagged tau protein, Thr175Ala tau or Thr175Asp tau. 12 months postinjection, all rats were investigated by immunohistochemistry for GFP (extent of vector expression), pThr231 tau protein, activated GSK3ß, and caspase-3 cleavage. Vector expression was primarily localized to hippocampal CA2 subregion. Tau protein pathology restricted to the CA2 region in the form of axonal beading, fibrils, and neurofibrillary tangles was observed in Thr175Asp tau inoculated brains and included colocalization with pThr231 tau and caspase-3 cleavage in this group only. Although no behavioral or imaging phenotype was observed, our results demonstrate that pThr175 tau protein is capable of exerting neuronal toxicity in vivo.
Subject(s)
Adenoviridae/metabolism , Gene Transfer Techniques , Genetic Vectors/metabolism , Hippocampus/metabolism , Threonine/metabolism , tau Proteins/metabolism , Adenoviridae/genetics , Animals , Female , Genetic Vectors/genetics , Hippocampus/pathology , Humans , Phosphorylation/physiology , Rats , Rats, Sprague-Dawley , Reflex, Startle/physiology , Threonine/genetics , tau Proteins/geneticsABSTRACT
Approximately 50-60% of all patients with amyotrophic lateral sclerosis (ALS) will develop a deficit of frontotemporal function, ranging from frontotemporal dementia (FTD) to one or more deficits of neuropsychological, speech or language function which are collectively known as the frontotemporal spectrum disorders of ALS (ALS-FTSD). While the neuropathology underlying these disorders is most consistent with a widespread alteration in the metabolism of transactive response DNA-binding protein 43 (TDP-43), in both ALS with cognitive impairment (ALSci) and ALS with FTD (ALS-FTD; also known as MND-FTD) there is evidence for alterations in the metabolism of the microtubule associated protein tau. This alteration in tau metabolism is characterized by pathological phosphorylation at residue Thr175 (pThr175 tau) which in vitro is associated with activation of GSK3ß (pTyr216GSK3ß), phosphorylation of Thr231tau, and the formation of cytoplasmic inclusions with increased rates of cell death. This putative pathway of pThr175 induction of pThr231 and the formation of pathogenic tau inclusions has been recently shown to span a broad range of tauopathies, including chronic traumatic encephalopathy (CTE) and CTE in association with ALS (CTE-ALS). This pathway can be experimentally triggered through a moderate traumatic brain injury, suggesting that it is a primary neuropathological event and not secondary to a more widespread neuronal dysfunction. In this review, we discuss the neuropathological underpinnings of the postulate that ALS is associated with a tauopathy which manifests as a FTSD, and examine possible mechanisms by which phosphorylation at Thr175tau is induced. We hypothesize that this might lead to an unfolding of the hairpin structure of tau, activation of GSK3ß and pathological tau fibril formation through the induction of cis-Thr231 tau conformers. A potential role of TDP-43 acting synergistically with pathological tau metabolism is proposed.
ABSTRACT
See Fratta and Isaacs (doi:10.1093/brain/awy091) for a scientific commentary on this article.The RNA binding proteins TDP-43 (encoded by TARDBP) and hnRNP A1 (HNRNPA1) are each mutated in certain amyotrophic lateral sclerosis cases and are often mislocalized in cytoplasmic aggregates within motor neurons of affected patients. Cytoplasmic inclusions of TDP-43, which are accompanied by a depletion of nuclear TDP-43, are observed in most amyotrophic lateral sclerosis cases and nearly half of frontotemporal dementia cases. Here, we report that TDP-43 binds HNRNPA1 pre-mRNA and modulates its splicing, and that depletion of nuclear TDP-43 results in increased inclusion of a cassette exon in the HNRNPA1 transcript, and consequently elevated protein levels of an isoform containing an elongated prion-like domain, referred to as hnRNP A1B. Combined in vivo and in vitro approaches demonstrated greater fibrillization propensity for hnRNP A1B, which drives protein aggregation and is toxic to cells. Moreover, amyotrophic lateral sclerosis patients with documented TDP-43 pathology showed neuronal hnRNP A1B cytoplasmic accumulation, indicating that TDP-43 mislocalization may contribute to neuronal vulnerability and loss via altered HNRNPA1 pre-mRNA splicing and function. Given that TDP-43 and hnRNP A1 each bind, and thus modulate, a third of the transcriptome, our data suggest a much broader disruption in RNA metabolism than previously considered.
Subject(s)
Alternative Splicing/genetics , Amyotrophic Lateral Sclerosis/genetics , Amyotrophic Lateral Sclerosis/metabolism , DNA-Binding Proteins/metabolism , Heterogeneous Nuclear Ribonucleoprotein A1/genetics , Protein Aggregation, Pathological/metabolism , Alternative Splicing/drug effects , Cell Death/drug effects , Cell Death/genetics , Cytoplasm/drug effects , Cytoplasm/metabolism , DNA-Binding Proteins/genetics , Dactinomycin/pharmacology , Gene Expression Regulation/drug effects , Gene Expression Regulation/genetics , HEK293 Cells , HeLa Cells , Heterogeneous Nuclear Ribonucleoprotein A1/metabolism , Humans , Immunoprecipitation , Motor Neurons/drug effects , Motor Neurons/metabolism , Mutation/genetics , Nucleic Acid Synthesis Inhibitors/pharmacology , Oligopeptides/genetics , Oligopeptides/metabolism , RNA Splice Sites/drug effects , RNA Splice Sites/genetics , RNA, Messenger/metabolism , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Spinal Cord/pathology , TransfectionABSTRACT
OBJECTIVE: To investigate whether chronic traumatic encephalopathy (CTE) and CTE with amyotrophic lateral sclerosis (CTE-ALS) exhibit features previously observed in other tauopathies of pathologic phosphorylation of microtubule-associated protein tau at Thr175 (pThr175 tau) and Thr231 (pThr231 tau), and glycogen synthase kinase-3ß (GSK3ß) activation, and whether these pathologic features are a consequence of traumatic brain injury (TBI). METHODS: Tau isoform expression was assayed by western blot in 6 stage III CTE cases. We also used immunohistochemistry to analyze 5 cases each of CTE, CTE-ALS, and 5 controls for expression of activated GSK3ß, pThr175 tau, pThr231 tau, and oligomerized tau within spinal cord tissue and hippocampus. Using a rat model of moderate TBI, we assessed tau pathology and phospho-GSK3ß expression at 3 months postinjury. RESULTS: CTE and CTE-ALS are characterized by the presence of all 6 tau isoforms in both soluble and insoluble tau isolates. Activated GSK3ß, pThr175 tau, pThr231 tau, and oligomerized tau protein expression was observed in hippocampal neurons and spinal motor neurons. We observed tau neuronal pathology (fibrillar inclusions and axonal damage) and increased levels of pThr175 tau and activated GSK3ß in moderate TBI rats. CONCLUSIONS: Pathologic phosphorylation of tau at Thr175 and Thr231 and activation of GSK3ß are features of the tauopathy of CTE and CTE-ALS. These features can be replicated in an animal model of moderate TBI.
Subject(s)
Amyotrophic Lateral Sclerosis/complications , Amyotrophic Lateral Sclerosis/metabolism , Chronic Traumatic Encephalopathy/complications , Chronic Traumatic Encephalopathy/metabolism , Threonine/metabolism , tau Proteins/metabolism , Amyotrophic Lateral Sclerosis/pathology , Animals , Chronic Traumatic Encephalopathy/pathology , Disease Models, Animal , Female , Gene Expression Regulation/physiology , Glycogen Synthase Kinase 3 beta/metabolism , Hippocampus/metabolism , Humans , Male , Phosphorylation , Rats , Rats, Sprague-Dawley , Spinal Cord/pathologyABSTRACT
Microtubule associated protein tau (tau) deposition is associated with a spectrum of neurodegenerative diseases collectively termed tauopathies. We have previously shown that amyotrophic lateral sclerosis (ALS) with cognitive impairment (ALSci) is associated with tau phosphorylation at Thr175 and that this leads to activation of GSK3ß which then induces phosphorylation at tau Thr231. This latter step leads to dissociation of tau from microtubules and pathological tau fibril formation. To determine the extent to which this pathway is unique to ALS, we have investigated the expression of pThr175 tau and pThr231 tau across a range of frontotemporal degenerations. Representative sections from the superior frontal cortex, anterior cingulate cortex (ACC), amygdala, hippocampal formation, basal ganglia, and substantia nigra were selected from neuropathologically confirmed cases of Alzheimer's disease (AD; n = 3), vascular dementia (n = 2), frontotemporal lobar degeneration (FTLD; n = 4), ALS (n = 5), ALSci (n = 6), Parkinson's disease (PD; n = 5), corticobasal degeneration (CBD; n = 2), diffuse Lewy body dementia (DLBD; n = 2), mixed DLBD (n = 3), multisystem atrophy (MSA; n = 6) and Pick's disease (n = 1) and three neuropathologically-normal control groups aged 50-60 (n = 6), 60-70 (n = 6) and 70-80 (n = 8). Sections were examined using a panel of phospho-tau antibodies (pSer208,210, pThr217, pThr175, pThr231, pSer202 and T22 (oligomeric tau)). Across diseases, phospho-tau load was most prominent in layers II/III of the entorhinal cortex, amygdala and hippocampus. This is in contrast to the preferential deposition of phospho-tau in the ACC and frontal cortex in ALSci. Controls showed pThr175 tau expression only in the 7th decade of life and only in the presence of tau pathology and tau oligomers. With the exception of DLBD, we observed pThr175 co-localizing with pThr231 in the same cell populations as T22 positivity. This suggests that this pathway may be a common mechanism of toxicity across the tauopathies.
Subject(s)
Tauopathies/genetics , Tauopathies/metabolism , tau Proteins/genetics , tau Proteins/metabolism , Aged , Aged, 80 and over , Aging/metabolism , Aging/pathology , Brain/metabolism , Brain/pathology , Female , Humans , Male , Middle Aged , Neuroglia/metabolism , Neuroglia/pathology , Neurons/metabolism , Neurons/pathology , Phosphorylation , Tauopathies/pathologyABSTRACT
We have previously shown that amyotrophic lateral sclerosis with cognitive impairment can be characterized by pathologic inclusions of microtubule-associated protein tau (tau) phosphorylated at Thr(175) (pThr(175)) in association with GSK3ß activation. We have now examined whether pThr(175) induces GSK3ß activation and whether this leads to pathologic fibril formation through Thr(231) phosphorylation. Seventy-two hours after transfection of Neuro2A cells with pseudophosphorylated green fluorescent protein-tagged 2N4R tau (Thr(175)Asp), phosphorylated kinase glycogen synthase kinase 3 beta (active GSK3ß) levels were significantly increased as was pathologic fibril formation and cell death. Treatment with each of 4 GSK3ß inhibitors or small hairpin RNA knockdown of GSK3ß abolished fibril formation and prevented cell death. Inhibition of Thr(231) phosphorylation (Thr(231)Ala) prevented pathologic tau fibril formation, regardless of Thr(175) state, whereas Thr(231)Asp (pseudophosphorylated at Thr(231)) developed pathologic tau fibrils. Ser(235) mutations did not affect fibril formation, indicating an unprimed mechanism of Thr(231) phosphorylation. These findings suggest a mechanism of tau pathology by which pThr(175) induces GSK3ß phosphorylation of Thr(231) leading to fibril formation, indicating a potential therapeutic avenue for amyotrophic lateral sclerosis with cognitive impairment.